The treatment of Parkinson’s disease (PD) requires personalized care, a high degree of polypharmacy, and frequent adjustments to achieve symptom control throughout the disease course. Consequently, treatment paradigms in PD have become increasingly complex as the growing availability and uptake of new brands have bolstered disease management with an array of mechanistically distinct drug classes. In addition to the SOC levodopa and generically available mainstays in entrenched drug classes, physicians prescribe branded agents that target niche PD subpopulations with high unmet need (e.g., Sunovion’s Kynmobi, Supernus’s Gocovri, Acadia’s Nuplazid). With the PD therapy market poised to grow meaningfully—thanks to a dynamic pipeline of unique therapies designed to optimize and lengthen the benefits of levodopa, reduce the severity of levodopa-induced dyskinesia, and reduce the frequency and impact of motor response complications—understanding neurologists’ prescribing practices and decision points when treating PD is crucial for developers facing a competitive and evolving market.
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.
Markets covered: United States
Key companies: AbbVie, Acadia, Acorda, Amneal, Kyowa Kirin, Lundbeck, Neurocrine, Sunovion, Supernus
Key drugs: Duopa, Gocovri, Inbrija, Kynmobi, Neupro, Northera, Nourianz, Nuplazid, Ongentys, Rytary, Xadago, all generic mainstays
Primary research: Survey of 101 U.S. neurologists
Key insights provided